SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Synthetic Blood (SYBD) -- Ignore unavailable to you. Want to Upgrade?


To: t.gawarecki who wrote (232)9/1/1998 1:53:00 PM
From: Lance  Read Replies (1) | Respond to of 307
 
Thanks for the post...I saw the release on prodigy...looks good...
just another piece to the puzzle...next piece will be the completion
of the agreement with the Asian drug manufacturer..

Lance



To: t.gawarecki who wrote (232)9/1/1998 10:13:00 PM
From: Rick Hoffmann  Read Replies (1) | Respond to of 307
 
Verrry interestink! USPTO only has one patent assigned to SBI, und guess who the inventor ist.



To: t.gawarecki who wrote (232)9/7/1998 10:26:00 PM
From: Prospector  Respond to of 307
 
BIG COMPA-TI TION FOR (SYBD)

SANGUINE just down the road is in animal clinical trials at BATTELLE

this is a second generation drug...already been FDA approved.. new and improved version... you can pick this stock up fer a quarter this week bluelight special...

members.aol.com

I think PHER-02 is in the same ball park.. Dr Thomas Drees is headin up Sanguine former CEO of Green Cross...sound familar..

Prospector